Hengrui Medicine (01276.HK) and its subsidiaries received drug clinical trial approval notices for injection SHR-A1811, Adalimumab injection, and Faronite Capsules.

Zhixin Finance APP News, Hengrui Medicine (01276.HK) announced that recently, the company and its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Pharmaceutical Co., Ltd., have received approval from the National Medical Products Administration (hereinafter referred to as the "NMPA") to carry out clinical trials on the injection of SHR-A1811, Atezolizumab injection, and Famicitinib apple acid capsules.